TaqMan real-time PCR quantification strategy of CYP2D6 gene copy number for the LightCycler 2.0

Clinica Chimica Acta

Volumn 403, Issue 1-2, 2009, Pages 207-211

  Nguyen, Duc L ^a   Staeker, Julia ^a   Laika, Barbara ^a   Steimer, Werner ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

CYP2D6; Gene copy number; TaqMan real time PCR

Indexed keywords

CYTOCHROME P450 2D6;

ARTICLE; CONTROLLED STUDY; EXON; GENE DELETION; GENE NUMBER; GENETIC POLYMORPHISM; GENETIC SCREENING; HUMAN; INTRON; MEDICAL INSTRUMENTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

CYTOCHROME P-450 CYP2D6; GENE DOSAGE; HUMANS; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TAQ POLYMERASE; TIME FACTORS;

EID: 64849090751     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.03.007     Document Type: Article

References (32)

1. Kimura S., Umeno M., Skoda R.C., Meyer U.A., and Gonzalez F.J. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 45 (1989) 889-904
2. Evans W.E., and Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286 (1999) 487-491
3. Eichelbaum M., Ingelman-Sundberg M., and Evans W.E. Pharmacogenomics and individualized drug therapy. Annu Rev Med 57 (2006) 119-137
4. Ingelman-Sundberg M., Sim S.C., Gomez A., and Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116 (2007) 496-526
5. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. CYP2D6 allele nomenclature. http://www.cypalleles.ki.se/cyp2d6.htm. Accessed February 2009.
6. Bradford L.D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3 (2002) 229-243
7. McLeod H.L. Genetic strategies to individualize supportive care. J Clin Oncol 20 (2002) 2765-2767
8. Phillips K.A., Veenstra D.L., Oren E., Lee J.K., and Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286 (2001) 2270-2279
9. Lazarou J., Pomeranz B.H., and Corey P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279 (1998) 1200-1205
10. Steimer W., and Potter J.M. Pharmacogenetic screening and therapeutic drugs. Clin Chim Acta 315 (2002) 137-155
11. Sachse C., Brockmöller J., Bauer S., and Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60 (1997) 284-295
12. Dalén P., Dahl M.L., Bernal Ruiz M.L., Nordin J., and Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 63 (1998) 444-452
13. Griese E.U., Zanger U.M., Brudermanns U., et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8 (1998) 15-26
14. Zanger U.M., Fischer J., Raimundo S., et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11 (2001) 573-585
15. Dahl M.L., Johansson I., Bertilsson L., Ingelman-Sundberg M., and Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 274 (1995) 516-520
16. Schaeffeler E., Schwab M., Eichelbaum M., and Zanger U.M. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum Mutat 22 (2003) 476-485
17. Bodin L., Beaune P.H., and Loriot M. Determination of cytochrome P450 2D6 (CYP2D6) gene copy number by real-time quantitative PCR. J Biomed Biotechnol 2005 (2005) 248-253
18. Stüven T., Griese E.U., Kroemer H.K., Eichelbaum M., and Zanger U.M. Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. Pharmacogenetics 6 (1996) 417-421
19. Ji L., Pan S., Marti-Jaun J., Hänseler E., Rentsch K., and Hersberger M. Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. Clin Chem 48 (2002) 983-988
20. Müller B., Zöpf K., Bachofer J., and Steimer W. Optimized strategy for rapid cytochrome P450 2D6 genotyping by real-time long PCR. Clin Chem 49 (2003) 1624-1631
21. Steen V.M., Andreassen O.A., Daly A.K., et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 5 (1995) 215-223
22. Løvlie R., Daly A.K., Molven A., Idle J.R., and Steen V.M. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 392 (1996) 30-34
23. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001) 402-408
24. Brøsen K., and Gram L.F. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 36 (1989) 537-547
25. Chen S., Chou W.H., Blouin R.A., et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 60 (1996) 522-534
26. Spina E., Gitto C., Avenoso A., Campo G.M., Caputi A.P., and Perucca E. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol 51 (1997) 395-398
27. Kaiser R., Sezer O., Papies A., et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 20 (2002) 2805-2811
28. Aarskog N.K., and Vedeler C.A. Real-time quantitative polymerase chain reaction. A new method that detects both the peripheral myelin protein 22 duplication in Charcot-Marie-Tooth type 1A disease and the peripheral myelin protein 22 deletion in hereditary neuropathy with liability to pressure palsies. Hum Genet 107 (2000) 494-498
29. Gaedigk A., Ndjountché L., Divakaran K., et al. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin Pharmacol Ther 81 (2007) 242-251
30. Daly A.K., Fairbrother K.S., Andreassen O.A., London S.J., Idle J.R., and Steen V.M. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics 6 (1996) 319-328
31. Gaedigk A., and Coetsee C. The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements. Eur J Clin Pharmacol 64 (2008) 465-475
32. Gaedigk A., Bradford L.D., Alander S.W., and Leeder J.S. CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status. Drug Metab Dispos 34 (2006) 563-569